The U.S. Food and Drug Administration has approved a new non-opioid pain medication developed by Boston-based Vertex ...

Patrizia Cavazzoni, leader of the Food and Drug Administration’s Center for Drug Evaluation and Research, is leaving the agency on Jan. 18, the latest top official to exit as Donald Trump ...

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

C&EN’s tabulation follows approvals from the FDA’s Center for Drug Evaluation and Research; therefore, it does not include blood products, gene therapies, vaccines, and other therapies that ...

The Food and Drug Administration approved a new type of nonopioid painkiller, Journaxv, or suzetrigine, drugmaker Vertex ...

acting director of the FDA’s Center for Drug Evaluation and Research, said in a news release. “This action and the agency’s designations to expedite the drug’s development and review ...

FDA Approves Non-Opioid Treatment for Moderate to Severe Acute Pain as Agency Continues to Take Steps to Support New ...

The US Food and Drug Administration (FDA) has approved a new pain medication, suzetrigine, marking the first new type of pain reliever to be approved in over 20 years.The drug, sold under the brand ...

“Today’s approval is an important public health milestone in acute pain management,” Jacqueline Corrigan-Curay, acting director of the FDA’s Center for Drug Evaluation and ...

The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.

“It is the FDA’s role to ensure that drugs are safe and effective,” said Patrizia Cavazzoni, director of the FDA’s center for drug evaluation and research in a November statement.

It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.